Pioglitazone on Pancreatic Steatosis and Bone Health

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: National Institutes of Health (NIH)
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Fat level in the pancreas above 4% (measurement done by us with an MRI)

• English speaker

• over 21 years old

Exclusion Criteria:

• contraindication to MRI

• anemia

• pregnancy or desire to conceive

• use of unapproved medications

• prior pancreatic disease

• use of more then 2 alcoholic drinks every day